Cardiac Safety of Chronic Inhibition of the Myostatin-Activin Pathway with Bimagrumab in Healthy Older Adults - PubMed
3 hours ago
- #cardiac safety
- #myostatin-activin pathway
- #bimagrumab
- Study investigates cardiac safety of chronic myostatin-activin pathway inhibition with bimagrumab in healthy older adults.
- Randomized, double-blind, placebo-controlled trial with 68 participants aged 60-86 years.
- No clinically relevant changes in left ventricular mass index (LVMI) or left ventricular ejection fraction (LVEF) observed after six months.
- Bimagrumab increased lean body mass (LBM) by 5.5% and decreased fat mass (FM) by 14% compared to placebo.
- Findings support bimagrumab as a potential muscle-sparing intervention during weight loss with GLP-1 receptor agonists.